Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases.

Publication date: Sep 21, 2023

This study aimed to determine whether the introduction of anti-SARS-CoV-2 vaccines and the dominance of the omicron variant had a significant impact on the outcome of COVID-19 in patients with systemic autoimmune rheumatic diseases (SAIRDs). Using data entered to the Greek Rheumatology Society COVID-19 registry, we investigated the incidence of hospitalization and death due to COVID-19, during the successive periods of the pandemic according to the prevalent strain (wild-type, Alpha, Delta, Omicron) in vaccinated and unvaccinated patients. Variables independently associated with hospitalization and death were explored using multivariate regression analyses, while Kaplan-Meier curves were used to depict survival data. From August 2020 until June 30, 2022, 456 cases (70. 2% females) of COVID-19 with a mean age (+/- SD) of 51. 4 +/- 14. 0 years were reported. In unvaccinated patients, the proportions of hospitalization and death were 24. 5% and 4%, compared to 12. 5% and 0. 8% in the vaccinated group (p

Open Access PDF

Concepts	Keywords
Greek	Anti-SARS-CoV-2 vaccine
June	Autoimmune rheumatic disease
Rheumatic	COVID-19
Vaccinated	Mortality
	Omicron variant

Semantics

Type	Source	Name
disease	VO	vaccination
disease	MESH	COVID-19
disease	MESH	rheumatic diseases
disease	MESH	death
disease	VO	vaccinated
disease	VO	unvaccinated
disease	MESH	Long Covid
disease	MESH	infection
drug	DRUGBANK	Rituximab
disease	MESH	cardiovascular disease
disease	MESH	pulmonary disease
disease	VO	vaccine
disease	MESH	immunocompromised patients
disease	VO	population
disease	VO	report
disease	MESH	musculoskeletal diseases
disease	MESH	morbidities
disease	MESH	idiopathic inflammatory myopathies
disease	MESH	polymyalgia rheumatica
disease	MESH	arteritis
disease	MESH	syndromes
disease	MESH	sarcoidosis
disease	VO	dose
disease	VO	vaccine dose
disease	MESH	re infection
disease	VO	immunization
disease	VO	ANOVA
disease	MESH	arthritis
disease	MESH	erythema
disease	MESH	psoriatic arthritis
disease	MESH	axial spondyloarthritis
disease	MESH	vasculitis
disease	IDO	cell
disease	MESH	hypertension
disease	MESH	obesity
drug	DRUGBANK	Trestolone
drug	DRUGBANK	Coenzyme M
drug	DRUGBANK	Ritonavir
drug	DRUGBANK	Adenosine 5′-phosphosulfate
drug	DRUGBANK	Hydroxychloroquine
drug	DRUGBANK	Methotrexate
drug	DRUGBANK	Leflunomide
drug	DRUGBANK	Azathioprine
drug	DRUGBANK	Sulfasalazine
drug	DRUGBANK	Apremilast
drug	DRUGBANK	Cyclophosphamide
drug	DRUGBANK	Mycophenolic acid
drug	DRUGBANK	Ciclosporin
disease	MESH	rheumatoid arthritis
pathway	KEGG	Rheumatoid arthritis
disease	MESH	systemic lupus erythematosus
pathway	KEGG	Systemic lupus erythematosus
disease	MESH	antiphospholipid syndrome
disease	MESH	systemic sclerosis
disease	MESH	connective tissue disease
drug	DRUGBANK	Belimumab
disease	MESH	Diabetes mellitus
disease	MESH	Malignancy
disease	VO	effectiveness
drug	DRUGBANK	Esomeprazole
disease	MESH	vascular diseases
disease	VO	time
pathway	REACTOME	Reproduction
drug	DRUGBANK	Polyethylene glycol
disease	VO	vaccine effectiveness
disease	VO	effective
disease	MESH	Piedra
disease	MESH	breakthrough infections
disease	IDO	country

Original Article

(Visited 1 times, 1 visits today)